Shares of AbbVie ABBV, -1.18% were down 0.6% in premarket trading on Tuesday after the company completed a $1 billion acquisition of Syndesi Therapeutics SA. Syndesi is developing treatments for cognitive impairment and other symptoms associated with Alzheimer’s disease and major depressive disorder.
...read full article on Market Watch